198 related articles for article (PubMed ID: 33527838)
21. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
[TBL] [Abstract][Full Text] [Related]
22. Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors.
Fan Z; Liu X; Wang N; Yu S; Bi C; Si Y; Ling X; Liu C; Wang J; Sun H
J Cancer Res Clin Oncol; 2024 May; 150(5):253. PubMed ID: 38748285
[TBL] [Abstract][Full Text] [Related]
23. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
24. Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors.
Li ZR; Wang S; Yang L; Yuan XH; Suo FZ; Yu B; Liu HM
Eur J Med Chem; 2019 Mar; 166():432-444. PubMed ID: 30739825
[TBL] [Abstract][Full Text] [Related]
25. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy.
Chen Y; Jie W; Yan W; Zhou K; Xiao Y
Crit Rev Eukaryot Gene Expr; 2012; 22(1):53-9. PubMed ID: 22339659
[TBL] [Abstract][Full Text] [Related]
26. Histone Demethylase LSD1 Regulates Kidney Cancer Progression by Modulating Androgen Receptor Activity.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kwak C; Kim HH
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847068
[TBL] [Abstract][Full Text] [Related]
27. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
28. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
[TBL] [Abstract][Full Text] [Related]
29. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
30. LSD1 Histone Demethylase Assays and Inhibition.
Hayward D; Cole PA
Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
[TBL] [Abstract][Full Text] [Related]
31. Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases.
Niwa H; Umehara T
Epigenetics; 2017 May; 12(5):340-352. PubMed ID: 28277979
[TBL] [Abstract][Full Text] [Related]
32. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
[TBL] [Abstract][Full Text] [Related]
33. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
35. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
[TBL] [Abstract][Full Text] [Related]
36. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
Liu HM; Suo FZ; Li XB; You YH; Lv CT; Zheng CX; Zhang GC; Liu YJ; Kang WT; Zheng YC; Xu HW
Eur J Med Chem; 2019 Aug; 175():357-372. PubMed ID: 31096156
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
Wang S; Zhao LJ; Zheng YC; Shen DD; Miao EF; Qiao XP; Zhao LJ; Liu Y; Huang R; Yu B; Liu HM
Eur J Med Chem; 2017 Jan; 125():940-951. PubMed ID: 27769034
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration.
Callegari K; Maegawa S; Bravo-Alegria J; Gopalakrishnan V
Cell Commun Signal; 2018 Sep; 16(1):60. PubMed ID: 30227871
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties.
Dulla B; Kirla KT; Rathore V; Deora GS; Kavela S; Maddika S; Chatti K; Reiser O; Iqbal J; Pal M
Org Biomol Chem; 2013 May; 11(19):3103-7. PubMed ID: 23575971
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]